Rose Bengal Photodynamic Therapy for Fusarium Keratitis

This trial tests a new treatment called Rose Bengal Photodynamic Therapy (RB-PDT) for fusarium keratitis, a fungal eye infection that can cause vision loss. Researchers aim to determine if RB-PDT, combined with standard medications, can improve patient outcomes. Participants will be divided into two groups: one will receive RB-PDT, and the other will receive a sham treatment (placebo). The study seeks individuals diagnosed with fusarium keratitis who experience moderate to severe vision loss. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

Research has shown that Rose Bengal Photodynamic Therapy (RB-PDT) is generally safe for treating eye infections. Past studies reported no recurrence of infection or serious side effects. The treatment appears to protect crucial parts of the eye, such as the thin layer inside the cornea. Over 130 patients have received RB-PDT without major issues, indicating that it is well-tolerated, though individual experiences may vary. These findings may help prospective trial participants feel more informed about the treatment's safety.¹²³⁴⁵

Rose Bengal Photodynamic Therapy (RB-PDT) is unique because it offers a novel approach to treating Fusarium keratitis by utilizing light activation to target fungal infections directly. Unlike traditional antifungal treatments like natamycin and amphotericin B, which rely on chemical mechanisms alone, RB-PDT involves applying a photosensitive dye (Rose Bengal) that, when activated by light, produces reactive oxygen species to destroy the fungi. Researchers are excited about this therapy because it has the potential to enhance the effectiveness of existing antifungal treatments, possibly leading to quicker recovery times and improved outcomes for patients with this challenging eye condition.

Research has shown mixed results for Rose Bengal Photodynamic Therapy (RB-PDT) in treating fungal eye infections like Fusarium keratitis. One study successfully treated about 72% of patients with fungal keratitis using RB-PDT. This therapy creates special molecules that help kill the fungus causing the infection. Another study found that patients with Fusarium keratitis improved in about 39 days on average. Although some reports mention that RB-PDT doesn't penetrate the eye deeply, it still shows promise for infections resistant to many drugs. In this trial, participants in Group 1 will receive RB-PDT, while those in Group 2 will receive a sham RB-PDT for comparison.¹²⁶⁷⁸